2326 GMT - The threat of U.S. tariffs could see protective-garment manufacturer Ansell face the re-emergence of uneven demand due to customer destocking, UBS analysts write in a note. They tell clients that they have become more optimistic about full-year sales growth at Ansell's healthcare unit, but that there are some risks ahead. They highlight the possibility that customers have built up inventory ahead of potential tariffs, which would eventually hit demand as they then use up the stock. Ansell needs to deliver on first-half analyst earnings expectations to continue recent support for its stock, the UBS note adds. UBS lifts its target price 12.5% to A$36.00 and keeps a buy rating on the stock, which is up 0.4% at A$30.63. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
January 28, 2025 18:27 ET (23:27 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.